The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 9, 2015, Pages 386.e7-386.e13

  Nayan, Madhur ^a   Bhindi, Bimal ^a   Yu, Julie L ^b   Hermanns, Thomas ^a   Mohammed, Aza ^a   Hamilton, Robert J ^a   Finelli, Antonio ^a   Jewett, Michael A S ^a   Zlotta, Alexandre R ^c   Fleshner, Neil E ^a   Kulkarni, Girish S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cystectomy; Metformin; Mortality; Patient outcome assessment; Urinary bladder neoplasms

Indexed keywords

INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BLADDER CARCINOMA; CANCER SPECIFIC SURVIVAL; CYSTECTOMY; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; CARCINOMA, TRANSITIONAL CELL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; URINARY BLADDER NEOPLASMS;

AGED; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; CYSTECTOMY; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84940467397     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.05.024     Document Type: Article

References (31)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Stein J.P., Lieskovsky G., Cote R., Groshen S., Feng A.C., Boyd S., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
3. Madersbacher S., Hochreiter W., Burkhard F., Thalmann G.N., Danuser H., Markwalder R., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
4. Shariat S.F., Karakiewicz P.I., Palapattu G.S., Lotan Y., Rogers C.G., Amiel G.E., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006, 176:2414-2422. [discussion 22].
5. Margel D., Urbach D.R., Lipscombe L.L., Bell C.M., Kulkarni G., Austin P.C., et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013, 31:3069-3075.
6. Spratt D.E., Zhang C., Zumsteg Z.S., Pei X., Zhang Z., Zelefsky M.J. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013, 63:709-716.
7. Sadeghi N., Abbruzzese J.L., Yeung S.C., Hassan M., Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012, 18:2905-2912.
8. Garrett C.R., Hassabo H.M., Bhadkamkar N.A., Wen S., Baladandayuthapani V., Kee B.K., et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012, 106:1374-1378.
9. Skinner H.D., Crane C.H., Garrett C.R., Eng C., Chang G.J., Skibber J.M., et al. Metformin use and improved response to therapy in rectal cancer. Cancer Med 2013, 2:99-107.
10. Ko E.M., Walter P., Jackson A., Clark L., Franasiak J., Bolac C., et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2013, 132:438-442.
11. Gotlieb W.H., Saumet J., Beauchamp M.C., Gu J., Lau S., Pollak M.N., et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008, 110:246-250.
12. Kumar S., Meuter A., Thapa P., Langstraat C., Giri S., Chien J., et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 2013, 119:555-562.
13. Liu J., Li M., Song B., Jia C., Zhang L., Bai X., et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013, 31:264-270.
14. Luo Q., Hu D., Hu S., Yan M., Sun Z., Chen F. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 2012, 12:517.
15. Kato K., Gong J., Iwama H., Kitanaka A., Tani J., Miyoshi H., et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012, 11:549-560.
16. He X., Esteva F.J., Ensor J., Hortobagyi G.N., Lee M.H., Yeung S.C. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+breast cancer. Ann Oncol 2012, 23:1771-1780.
17. Zhang T., Guo P., Zhang Y., Xiong H., Yu X., Xu S., et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci 2013, 14:24603-24618.
18. Rieken M., Xylinas E., Kluth L., Crivelli J.J., Chrystal J., Faison T., et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int 2013, 112:1105-1112.
19. Rieken M., Xylinas E., Kluth L., Crivelli J.J., Chrystal J., Faison T., et al. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol 2014, 32:e7-e14.
20. Clarke E.A., Marrett L.D., Kreiger N. Cancer registration in Ontario: a computer approach. IARC Sci Publ 1991, 95:246-257.
21. Austin P.C., Mamdani M.M., van Walraven C., Tu J.V. Quantifying the impact of survivor treatment bias in observational studies. J Eval Clin Pract 2006, 12:601-612.
22. Lin D., Wei L.-J. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989, 84:1074-1078.
23. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
24. Maldonado G., Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993, 138:923-936.
25. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
26. Rieken M., Xylinas E., Kluth L., Trinh Q.D., Lee R.K., Fajkovic H., et al. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 2014, 40:113-120.
27. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
28. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med 2003, 349:859-866.
29. Campagnoli C., Pasanisi P., Abba C., Ambroggio S., Biglia N., Brucato T., et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer 2012, 12:175-182.
30. Gokcel A., Gumurdulu Y., Karakose H., Melek Ertorer E., Tanaci N., BascilTutuncu N., et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002, 4:49-55.
31. Stakos D.A., Schuster D.P., Sparks E.A., Wooley C.F., Osei K., Boudoulas H. Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study. Heart 2005, 91:589-594.